Results 11 to 20 of about 6,042 (221)

Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial

Arthritis Research & Therapy, 2023
Background Nail psoriasis is a common, physiologically, and psychologically disruptive, and yet often under-treated manifestation of psoriasis. The objectives of this analysis were to investigate the trajectory of nail psoriasis, a risk factor for ...
William Tillett, Alexander Egeberg, Enikö Sonkoly, Patricia Gorecki, Anna Tjärnlund, Jozefien Buyze, Sven Wegner, Dennis McGonagle   +7 more
doaj   +1 more source

Guselkumab in the treatment of patients with plaque psoriasis of moderate and severe severity: Efficacy and safety of interleukin-23 blockade

Vestnik Dermatologii i Venerologii, 2020
Materials and methods. In this paper, we review publications on the significance of interleukin-(IL)-23 in the pathogenesis of plaque psoriasis and analyse the results of the 1st and 2nd phase clinical studies, as well as the 3rd phase comparative ...
V. V. Chikin
doaj   +1 more source

Virus-Like Particle-Mediated Vaccination against Interleukin-13 May Harbour General Anti-Allergic Potential beyond Atopic Dermatitis [PDF]

, 2020
Virus-like particle (VLP)-based anti-infective prophylactic vaccination has been established in clinical use. Although validated in proof-of-concept clinical trials in humans, no VLP-based therapeutic vaccination against self-proteins to modulate chronic
Foerster, John, Molęda, Aleksandra
core   +2 more sources

Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis

Acta Dermato-Venereologica, 2022
Guselkumab treatment outcomes and persistence were assessed in a real-world cohort of Finnish patients with difficult-to-treat plaque psoriasis over a median follow-up of 1 year.
Tarja Mälkönen, Pauliina Nuutinen, Taru Hallinen, Erkki Soini, Riikka Nissinen, Christina Wennerstöm, Tapio Rantanen, Johanna H. Hagman, Rauno Harvima, Johanna Höök-Nikanne, Tiina Ilves, Päivi Lintu, Ken Malanin, Iina Soramäki, Kaisa Tasanen, Arja Teho, Katja Vähävihu, Sari Itälinna, Pekka Leinonen, Piia Sarajärvi, Laura Huilaja, Rafael Pasternack   +21 more
doaj   +1 more source

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial

Trials, 2023
Background Guselkumab, a fully human monoclonal antibody targeting the interleukin (IL)-23p19 subunit, is approved to treat adults with active psoriatic arthritis (PsA).
Christopher T. Ritchlin, Laura C. Coates, Philip J. Mease, Désirée van der Heijde, Jiao Song, Yusang Jiang, May Shawi, Alexa P. Kollmeier, Proton Rahman   +8 more
doaj   +1 more source

Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials

RMD Open, 2021
Objective To investigate serum protein expression in participants with psoriatic arthritis (PsA) and changes after guselkumab treatment.Methods Participants with PsA were treated with guselkumab or placebo in the DISCOVER-1 and DISCOVER-2 studies.
Kristen Sweet, Matthew J Loza, Philip Cooper, Qingxuan Song, Keying Ma, Karen Leander, Vani Lakshminarayanan, Carol Franks   +7 more
doaj   +1 more source

Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab

Dermatology and Therapy, 2023
Guselkumab is an anti-interleukin-23 monoclonal antibody that is approved for plaque psoriasis and psoriatic arthritis. We present a case of a 28-year-old female patient with acute onset of guttate psoriasis after a blistering sunburn.
Erin Bartholomew, Bo-Young Chung, Mitchell Davis, Samuel Yeroushalmi, Mimi Chung, Marwa Hakimi, Tina Bhutani, Wilson Liao   +7 more
doaj   +1 more source

Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo‐Controlled Trials

ACR Open Rheumatology, 2023
Objective To evaluate gene expression in blood of patients with psoriatic arthritis (PsA) versus healthy controls and identify changes associated with guselkumab treatment.
Stefan Siebert, Kristen M. Sweet, Christopher T. Ritchlin, Elizabeth C. Hsia, Alexa P. Kollmeier, Xie L. Xu, Loqmane Seridi, Qingxuan Song, Sheng Gao, Warner Chen, Michelle Miron   +10 more
doaj   +1 more source

Effect of guselkumab on serum biomarkers in Japanese palmoplantar pustulosis patients in a randomized phase 3 study

JEADV Clinical Practice, 2023
Background It is reported that treatment of palmoplantar pustulosis (PPP) with guselkumab has greater improvement in clinical responses in terms of palmoplantar pustulosis area severity index (PPPASI) score. Here, we present the effect of guselkumab (100
Akimichi Morita, Yanqing Chen, Monica W. L. Leung, Naoko Kawashima, Tadashi Terui   +4 more
doaj   +1 more source

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced

RMD Open, 2021
Objective Evaluation of the efficacy and safety of guselkumab, a human monoclonal antibody targeting the interleukin-23p19 subunit, in patients with psoriatic arthritis (PsA) through 1 year.Methods Adults who met ClASsification criteria for Psoriatic ...
Atul Deodhar, Shihong Sheng, Philip S Helliwell, Soumya D Chakravarty, Elizabeth C Hsia, Enrique R Soriano, Chetan S Karyekar, Wolf-Henning Boehncke, Prasheen Agarwal, Christopher T Ritchlin, Alexa P Kollmeier, Federico Zazzetti, Ramanand A Subramanian, Xie L Xu, Qing C Zuraw, Yusang Jiang, Bei Zhou, Yanli Zhuang, May Shawi   +18 more
doaj   +1 more source